CAR T-cell therapy

In December 2018 the Australian Therapeutic Goods Administrator (TGA) approved the use of chimeric antigen receptor T cell (CAR-T cell) therapy for two types of blood cancer, diffuse large B cell lymphoma (DLBCL) and B

Read More
Snowflake Snowflake Snowflake Snowflake Snowflake Snowflake

You can help more than you know

Please donate now